- According to an analysis of data from ClinicalTrials.gov, more than 200 interventional oncology clinical trials were suspended in March and April 2020 because of the COVID-19 pandemic.
- Another survey indicates that most institutions in the United States and Europe are enrolling new patients at lower rates.
Why this matters
- The COVID-19 pandemic has caused significant disruption in clinical research globally.
- A survey of 36 investigators showed that only 20% and 14% of institutions in the United States and Europe, respectively, continued to enroll patients at the usual rate.
- In contrast, 60% of institutions in Asia reported no change in enrollment rates.
- 60% of investigators stated that COVID-19 had "moderate" or "high" impact on causing delayed or canceled patient visits.
- Data from ClinicalTrials.gov showed that 62 interventional oncology trials were suspended in March and 139 in April.
- Of these, 29 were phase 1, 72 were phase 2, 11 were phase 3, and the rest were classified as "other."
- A separate analysis of a subset of clinical trials run by IQVIA showed that milestone delays (16%) were the most reported risk as a result of the COVID-19 pandemic.